2-methylbut-3-yn-2-ol

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Comparable to guideline study with acceptable restrictions

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference 1

Reference Type:

other company data

Title:

Unnamed

Year:

1966

Report date:

1966

Reference 2

Reference Type:

secondary source

Title:

SIDS Initial Assessment Report - 2-Methylbut-3-yn-ol

Author:

BASF AG

Year:

2002

Bibliographic source:

OECD SIDS

Reference 3

Reference Type:

secondary source

Title:

Unnamed

Year:

2000

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Principles of method if other than guideline:

Internal methods which were in large part similar to the methods described in OECD Guideline 401

GLP compliance:

no

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2-methylbut-3-yn-2-ol

EC Number:

204-070-5

EC Name:

2-methylbut-3-yn-2-ol

Cas Number:

115-19-5

Molecular formula:

C5H8O

IUPAC Name:

2-methylbut-3-yn-2-ol

Details on test material:

- Analytical purity: 98.5%

Test animals

Species:

rat

Strain:

not specified

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: mean 242 g (male), 185 g( female)

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 2, 16, 20%
- Amount of vehicle (if gavage): 10 ml/kg bw

Doses:

0.2, 1.25, 1.6, 2.00 ml/kg bw (= ca. 172, 1076, 1377, 1722 mg/kg bw)

No. of animals per sex per dose:

10

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations and weighing: daily
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs and mortality

Results and discussion

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LD50

Effect level:

1.65 mL/kg bw

Effect levels 2

Sex:

male/female

Dose descriptor:

LD50

Effect level:

1 420 mg/kg bw

Mortality:

2.000 ml/kg bw: 8/10 within 48 h; 10/10 within 7 days
1.60 ml/kg bw: 4/10 within 24 h
1.25 ml/kgbw : 1/10 within 24 h
0.20 ml/kg bw: 0/10 within 7 days

Clinical signs:

other: 1.60 -2.00 ml/kg bw: - shortly after application: staggering, apathy, dyspnea, abdominal and lateral position, - after 10 -30 minutes: narcosis - after 5 h: narcosis, discharge of the eyes - 48 h: abdominal and lateral position, narcosis - days 3-4: int

Gross pathology:

- 3x hydrothorax, collapse of lung, blood in renal capsule, blood in urine at 2.0 ml/kg bw
- organs: no effects

Applicant's summary and conclusion

Interpretation of results:

harmful

Remarks:

Migrated information Criteria used for interpretation of results: EU